Cargando…

Long-term remission of a Her2/neu positive primary breast cancer under double monoclonal antibody therapy with trastuzumab and bevacizumab

BACKGROUND: The attempt to act on several signalling pathways involved in tumour development simultaneously appears to be more attractive than attacking a single target structure alone. Vascular endothelial growth factor (VEGF) over-expression is frequently observed in human epidermal growth factor...

Descripción completa

Detalles Bibliográficos
Autores principales:	Königsberg, Robert, Maierhofer, Julia, Steininger, Tanja, Kienzer, Gabriele, Dittrich, Christian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Versita, Warsaw 2014
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4078037/ https://www.ncbi.nlm.nih.gov/pubmed/24991208 http://dx.doi.org/10.2478/raon-2013-0083

Ejemplares similares

Pro1170 Ala polymorphism in HER2-neu is associated with risk of trastuzumab cardiotoxicity
por: Stanton, Sasha E, et al.
Publicado: (2015)

Trastuzumab for Her2/neu-positive metastatic salivary gland carcinoma: Case report and review of the literature
por: Firwana, Belal, et al.
Publicado: (2012)

Computational model to explore the endocrine response to trastuzumab action in HER-2/neu positive breast cancer
por: Wang, Fuzhang, et al.
Publicado: (2022)

Binding Affinity of Trastuzumab and Pertuzumab Monoclonal Antibodies to Extracellular HER2 Domain †
por: Cruz, Victor L., et al.
Publicado: (2023)

Is there any advantage to combined trastuzumab and chemotherapy in perioperative setting her 2neu positive localized gastric adenocarcinoma?
por: Sbitti, Yassir, et al.
Publicado: (2011)

Palmitate-induced ER stress increases trastuzumab sensitivity in HER2/neu-positive breast cancer cells
por: Baumann, Jan, et al.
Publicado: (2016)

Her2/neu extracellular domain shedding in uterine serous carcinoma: implications for immunotherapy with trastuzumab
por: Todeschini, P, et al.
Publicado: (2011)

The Predictive Value of Serum HER2/neu for Response to Anthracycline-Based and Trastuzumab-Based Neoadjuvant Chemotherapy
por: Lee, Jung Sun, et al.
Publicado: (2012)

Plant-Made Trastuzumab (Herceptin) Inhibits HER2/Neu+ Cell Proliferation and Retards Tumor Growth
por: Komarova, Tatiana V., et al.
Publicado: (2011)

CPT-11/bevacizumab for the treatment of refractory brain metastases in patients with HER2–neu-positive breast cancer
por: Sengupta, S., et al.
Publicado: (2015)

Autophagy Facilitates the Development of Breast Cancer Resistance to the Anti-HER2 Monoclonal Antibody Trastuzumab
por: Vazquez-Martin, Alejandro, et al.
Publicado: (2009)

Antibody–Drug Conjugates (ADC) in HER2/neu-Positive Gynecologic Tumors
por: McNamara, Blair, et al.
Publicado: (2023)

Successful Treatment of HER2-neu–positive Breast Cancer With Paclitaxel and Trastuzumab Supplemented With Turkey Tail Mushrooms and Community Support
por: Smith, Julie
Publicado: (2012)

Societal Costs and Benefits of Treatment with Trastuzumab in Patients with Early HER2neu-Overexpressing Breast Cancer in Singapore
por: de Lima Lopes, Gilberto
Publicado: (2011)

Selection of HER2/NEU negative tumor cells as a mechanism of resistance to trastuzumab in uterine serous carcinoma
por: Pelligra, Silvia, et al.
Publicado: (2020)

Dose escalation and pharmacokinetic study of a humanized anti-HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer
por: Tokuda, Y, et al.
Publicado: (1999)

At least two Fc Neu5Gc residues of monoclonal antibodies are required for binding to anti-Neu5Gc antibody
por: Yu, Chuanfei, et al.
Publicado: (2016)

Trastuzumab mediates antibody-dependent cell-mediated cytotoxicity and phagocytosis to the same extent in both adjuvant and metastatic HER2/neu breast cancer patients
por: Petricevic, Branka, et al.
Publicado: (2013)

Anti-Her-2/neu antibody induces apoptosis in Her-2/neu overexpressing breast cancer cells independently from p53 status
por: Brodowicz, T, et al.
Publicado: (2001)

Erratum: At least two Fc Neu5Gc residues of monoclonal antibodies are required for binding to anti-Neu5Gc antibody
por: Yu, Chuanfei, et al.
Publicado: (2017)

Conjugation of Monoclonal Antibodies to Super Paramagnetic Iron Oxide Nanoparticles for Detection of her2/neu Antigen on Breast Cancer Cell Lines
por: Shamsipour, Fereshteh, et al.
Publicado: (2009)

A New Monoclonal Antibody Demonstrates That Muc4, the Intramembrane Ligand for Erbb2/Her2/Neu, Is Overexpressed in Multiple Carcinomas
por: Zhang, Jin, et al.
Publicado: (2002)

Efficacy control of therapy using circulating epithelial tumor cells (CETC) as “Liquid Biopsy”: trastuzumab in HER2/neu-positive breast carcinoma
por: Pachmann, Katharina, et al.
Publicado: (2011)

Breast Cancer and Her-2/Neu
por: Sherwood, Roy
Publicado: (2005)

Trastuzumab Mediated T-Cell Response against HER-2/Neu Overexpressing Esophageal Adenocarcinoma Depends on Intact Antigen Processing Machinery
por: Milano, Francesca, et al.
Publicado: (2010)

Regression of metastatic, radiation/chemotherapy-resistant uterine serous carcinoma overexpressing HER2/neu with trastuzumab emtansine (TDM-1)
por: Santin, Alessandro D., et al.
Publicado: (2016)

Adjuvant effect of HER-2/neu-specific adenoviral vector stimulating CD8(+) T and natural killer cell responses on anti-HER-2/neu antibody therapy for well-established breast tumors in HER-2/neu transgenic mice
por: Chen, Y, et al.
Publicado: (2011)

Immunogenicity of rat-neu(+) mouse mammary tumours determines the T cell-dependent therapeutic efficacy of anti-neu monoclonal antibody treatment
por: Sow, Heng Sheng, et al.
Publicado: (2020)

Monoclonal Antibody Functionalized, and L-lysine α-Oxidase Loaded PEGylated-Chitosan Nanoparticle for HER2/Neu Targeted Breast Cancer Therapy
por: Saravanakumar, Kandasamy, et al.
Publicado: (2022)

Prognostic relevance of HER2/neu in acute lymphoblastic leukemia and induction of NK cell reactivity against primary ALL blasts by trastuzumab
por: Haen, Sebastian P., et al.
Publicado: (2016)

Long-term tumor remission under trastuzumab treatment for HER2 positive metastatic breast cancer – results from the HER-OS patient registry
por: Witzel, Isabell, et al.
Publicado: (2014)

HER-2/neu diagnostics in breast cancer
por: Carney, Walter P, et al.
Publicado: (2007)

The Clinical Importance of the Heterogeneity of HER2 neu
por: Davila, Enrique, et al.
Publicado: (2010)

Clinical and prognostic profile of Her2neu positive (non-luminal) intrinsic breast cancer subtype: comparison with Her2neu positive luminal breast cancers
por: Hashmi, Atif Ali, et al.
Publicado: (2018)

The vitamin E analog, alpha-tocopheryloxyacetic acid enhances the anti-tumor activity of trastuzumab against HER2/neu-expressing breast cancer
por: Hahn, Tobias, et al.
Publicado: (2011)

Measuring the Pharmacodynamic Effects of a Novel Hsp90 Inhibitor on HER2/neu Expression in Mice Using (89)Zr-DFO-Trastuzumab
por: Holland, Jason P., et al.
Publicado: (2010)

Carcinomatous meningitis in a patient with Her2/neu expressing bladder cancer following trastuzumab and chemotherapy: a case report and review of the literature
por: Goodman, Oscar B, et al.
Publicado: (2009)

PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2/neu overexpressing uterine serous carcinomas
por: Black, Jonathan D, et al.
Publicado: (2015)

PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2/neu overexpressing uterine serous carcinomas
por: Black, Jonathan D, et al.
Publicado: (2015)

Factors Influencing Lymph Node Positivity in HER2/neu+ Breast Cancer Patients
por: Englander, Katherine, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_e3ujit8loo1gs3saiqpop1k02e